Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.

Date publication

mai 2016

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Dr RIOS Maria

Tous les auteurs :
Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A, Italiano A, Bouché O, Chauzit E, Duffaud F, Bertucci F, Isambert N, Gautier J, Blay JY, Pérol D,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27068858

Résumé

Gastrointestinal stromal tumours (GIST) are the most common mesenchymal neoplasms of the gastrointestinal tract. Imatinib followed by sunitinib and regorafenib is the standard sequence of treatment for advanced disease. Pazopanib is effective in soft tissue sarcomas but has never been assessed in advanced GIST in a randomised trial. We aimed to assess the efficacy and safety of pazopanib in patients with previously treated advanced GIST.

Mots clés

Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Disease-Free Survival, Drug Resistance, Neoplasm, drug effects, Drug-Related Side Effects and Adverse Reactions, classification, Female, France, Gastrointestinal Stromal Tumors, drug therapy, Humans, Imatinib Mesylate, administration & dosage, Indoles, administration & dosage, Male, Middle Aged, Neoplasm Staging, Protein Kinase Inhibitors, administration & dosage, Pyrimidines, administration & dosage, Pyrroles, administration & dosage, Sulfonamides, administration & dosage, Sunitinib, Treatment Outcome

Référence

Lancet Oncol.. 2016 May;17(5):632-41